Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245388 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT00245388 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 330 participants.
The verdict
NCT00245388, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with pravastatin in subjects with mixed dyslipidemia.
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2002-04 |
| Est. Completion | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245388
The ClinicalTrials.gov registry entry for NCT00245388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00245388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245388 about?
NCT00245388 is a clinical study titled "Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia". This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with pravastatin in subjects with mixed dyslipidemia.
What is the current status of trial NCT00245388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2002-04. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00245388?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00245388?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.